<?xml version="1.0" encoding="UTF-8"?>
<p>Patients in the IFN group received IFN β-1a in addition to the national protocol medications. Each 44-μg/ml (12 million IU/ml) dose of interferon β-1a (ReciGen, CinnaGen Co., Iran) was subcutaneously injected three times weekly for two consecutive weeks. The control group received only the standard of care. The standard of care (the hospital protocol) consisted of hydroxychloroquine (400 mg twice a day [BID] on the first day and then 200 mg BD) plus lopinavir-ritonavir (400 and 100 mg, respectively, BD) or atazanavir-ritonavir (300 and 100 mg, respectively, daily) for 7–10 days. Primary care, respiratory support, fluid, electrolyte, analgesic, antipyretic, corticosteroid, and antibiotic treatments were recommended in the hospital protocol if indicated. The duration of the study was 2 weeks, and the patients were monitored for 4 weeks.</p>
